Inclusion Criteria:

   - Biopsy proven prostate adenocarcinoma

   - Rising PSA after definitive therapy with prostatectomy or radiation therapy (external
   beam or brachytherapy

      - Post radical prostatectomy (RP) - American Urological Association (AUA)
      recommendation

         - PSA greater than 0.2 ng/mL measured 6-13 weeks after RP

         - Confirmatory persistent PSA greater than 0.2 ng/mL

      - Post-radiation therapy - American Society for Therapeutic Radiology and Oncology
      (ASTRO)-Phoenix consensus definition

         - Nadir plus (+) greater than or equal to 2 ng/mL rise in PSA

   - No evidence of metastatic disease on conventional imaging, including a negative bone
   scan for skeletal metastasis and negative contrast-enhanced CT

   - Able to provide written consent

   - Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group
   [ECOG]/World Health Organization [WHO] equivalent)

Exclusion Criteria:

   - Unable to provide informed consent

   - Inability to lie still for the entire imaging time

   - Inability to complete the needed investigational and standard-of-care imaging
   examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

   - Any additional medical condition, serious intercurrent illness, or other extenuating
   circumstance that, in the opinion of the investigator, may significantly interfere
   with study compliance

   - Metallic implants